NextRNA explored therapeutic applications utilizing long non-coding RNAs (lncRNAs) to address unmet medical needs. The company focused on developing novel modalities within the RNA space for serious diseases. Their work aimed to advance the understanding and treatment potential of lncRNAs in oncology and other indications.
Funding
$56.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CVFounders
Product
Problem
Long non-coding RNAs (lncRNAs) play a role in various diseases by interacting with RNA-binding proteins (RBPs) to drive pathological processes. Targeting these lncRNA-RBP interactions presents a challenge due to the complexity and diversity of lncRNAs. Current therapeutic approaches have yet to fully exploit the potential of modulating lncRNA function for disease treatment.
Solution
NextRNA Therapeutics is developing small molecule therapeutics designed to inhibit lncRNA function by selectively disrupting their interactions with RBPs. This approach aims to address diseases driven by lncRNAs, particularly in oncology and neuroscience. The company's proprietary platform identifies tissue-specific and disease-driving lncRNAs, validates their role in disease mechanisms, and develops small molecules to modulate lncRNA-RBP interactions. By targeting these interactions, NextRNA seeks to develop transformative medicines that address the underlying causes of lncRNA-driven diseases.
Target Audience
The primary target audience includes patients suffering from diseases driven by long non-coding RNAs (lncRNAs), as well as pharmaceutical companies seeking novel therapeutic approaches in oncology and neuroscience.
Features
- Identification of tissue-specific and disease-driving lncRNAs across therapeutic areas.
- Validation of lncRNA's role and characterization of lncRNA-RBP interactions in disease mechanisms.
- Development of functional small molecules to inhibit lncRNA function.
- Disruption of lncRNA-RBP interactions with small molecules.
- Proprietary platform for target discovery and drug development.